secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123256
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma completes Phase 3 enrollment in pulmonary sarcoidosis; topline data Q3 2025
--------------------------------------------------------------------------------

- Phase 3 EFZO-FIT enrolled 268 patients (target exceeded) at 85 centers in 9 countries; topline data expected Q3 2025.
- Cash, equivalents, and investments $68.9M at Sep 30, 2024; raised ~$19.4M in ATM offering post-quarter.
- R&D expenses $14.8M and G&A $3.3M in Q3 2024; cash runway projected through BLA filing for efzofitimod.
- Publication in European Respiratory Journal showed significant reduction in corticosteroid relapse with efzofitimod.
- Phase 2 EFZO-CONNECT in SSc-ILD enrolling; interim data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024123256/0000950170-24-123256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017024123256/atyr-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer